ADC Therapeutics S.A. (ADCT)
NYSE: ADCT
· Real-Time Price · USD
3.46
-0.10 (-2.81%)
At close: Sep 25, 2025, 10:09 AM
ADC Therapeutics S.A. Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Jun 30, 2023 | Mar 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Product Revenue | 18.09M | 17.4M | 33.42M | 18.02M | 17.03M | 17.85M | 373K | 86K | 39K |
| Product Revenue Growth | +3.91% | -47.92% | +85.48% | +5.79% | -4.58% | +4684.99% | +333.72% | +120.51% | n/a |
| Royalty Revenue Revenue | 754K | 629K | 904K | 448K | 380K | 205K | n/a | n/a | n/a |
| Royalty Revenue Revenue Growth | +19.87% | -30.42% | +101.79% | +17.89% | +85.37% | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Jun 30, 2023 | Mar 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Emea Revenue | 754K | 5.63M | 904K | 448K | 380K | 205K | 373K | 86K | 39K |
| Emea Revenue Growth | -86.61% | +522.68% | +101.79% | +17.89% | +85.37% | -45.04% | +333.72% | +120.51% | n/a |
| United States Revenue | 18.09M | 17.4M | 33.42M | 18.02M | 17.03M | 17.85M | 30.91M | 19.2M | 18.95M |
| United States Revenue Growth | +3.91% | -47.92% | +85.48% | +5.79% | -4.58% | -42.26% | +61.01% | +1.29% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 18.97M | -598K | 20.87M | 20.68M | 20.94M | 23.42M | 25.22M | 23.09M | 26.46M | 30.49M | 31.31M | 36.46M | 35.9M | 37.38M | 36.53M | 33.63M | 34.59M | 31.49M | 29.45M | 20.27M | 19M | 8.51M | 4.92M | 2.3M | 4.09M | 3.3M | 2.4M | 2.4M | 1.98M | 1.98M |
| Selling, General, and Administrative Revenue Growth | -3272.07% | -102.86% | +0.96% | -1.26% | -10.60% | -7.14% | +9.23% | -12.73% | -13.24% | -2.62% | -14.12% | +1.57% | -3.96% | +2.33% | +8.61% | -2.76% | +9.83% | +6.94% | +45.26% | +6.71% | +123.25% | +72.97% | +113.73% | -43.70% | +24.06% | +37.36% | 0.00% | +20.91% | 0.00% | n/a |
| Research and Development Revenue | 30.09M | 28.93M | 27.1M | 32.5M | 24.3M | 25.73M | 30.33M | 28.44M | 31.94M | 39.48M | 48.73M | 41.68M | 48.54M | 48.95M | 42.49M | 36.8M | 39.53M | 39.17M | 48.55M | 32.16M | 25.95M | 35.38M | 30.42M | 30.54M | 21.76M | 23.29M | 29.09M | 29.09M | 30.07M | 30.07M |
| Research and Development Revenue Growth | +4.02% | +6.74% | -16.62% | +33.78% | -5.60% | -15.15% | +6.65% | -10.97% | -19.09% | -18.99% | +16.93% | -14.14% | -0.85% | +15.20% | +15.45% | -6.90% | +0.92% | -19.32% | +50.99% | +23.91% | -26.64% | +16.27% | -0.38% | +40.35% | -6.55% | -19.95% | 0.00% | -3.25% | 0.00% | n/a |
| Sales and Marketing Revenue | 4M | -10.55M | 5.72M | 5.06M | 4.85M | 5.81M | 13.93M | 8.04M | 8.33M | 15.35M | 16.18M | 8.24M | 17.66M | 18.37M | 18.6M | 17.05M | 15.22M | 13.91M | 9.35M | 6.12M | 4M | 2.63M | n/a | n/a | n/a | n/a | -50K | -50K | 50K | 50K |
| Sales and Marketing Revenue Growth | -137.95% | -284.36% | +13.21% | +4.25% | -16.55% | -58.27% | +73.33% | -3.53% | -45.74% | -5.10% | +96.41% | -53.36% | -3.87% | -1.25% | +9.14% | +11.98% | +9.42% | +48.73% | +52.93% | +52.75% | +52.36% | n/a | n/a | n/a | n/a | -100.00% | 0.00% | -200.00% | 0.00% | n/a |